Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 1.00 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.52 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.52 |
| ▸ | ROS1 | P08922 | 1/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.52 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21412815 | 1.00 | NTRK1 (1.00) | NTRK1NTRK3NTRK2ROS1TNK2 | |
| SCHEMBL2239197 | 1.00 | NTRK1 (1.00) | NTRK1NTRK3NTRK2ROS1TNK2 | |
| SCHEMBL21364723 | 0.82 | NTRK1 (0.70) | NTRK1NTRK3NTRK2ROS1TNK2 | |
| SCHEMBL22923183 | 0.81 | NTRK1 (0.68) | NTRK1NTRK3NTRK2ROS1TNK2 | |
| SCHEMBL2238233 | 0.79 | NTRK1 (0.64) | NTRK1SMPD3 | |
| SCHEMBL26561842 | 0.79 | NTRK1 (0.65) | NTRK1NTRK3NTRK2ROS1TNK2 | |
| SCHEMBL26561845 | 0.79 | NTRK1 (0.65) | NTRK1NTRK3NTRK2ROS1TNK2 | |
| SCHEMBL21365137 | 0.78 | NTRK1 (0.64) | NTRK1NTRK3NTRK2ROS1TNK2 | |
| SCHEMBL2237826 | 0.77 | NTRK1 (1.00) | NTRK1NTRK3NTRK2ROS1TNK2 | |
| SCHEMBL2237820 | 0.77 | NTRK1 (1.00) | NTRK1NTRK3NTRK2ROS1TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | NTRK1 2409/4885NTRK3 2974/4885NTRK2 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.